PTC Therapeutics Inc


PTCT

Price

43


Change

0.44


High

43.43


Low

42.07


Avg Volume

1,040,365


PE Ratio

-5.45


52 Week High

59.84


52 Week Low

25.01



Profile

PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. In 2020, PTC announced the FDA approval of Evrysdi™ for the treatment of spinal muscular atrophy in adults and children 2 months and older, in partnership with the SMA Foundation and Roche.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.